Healthcare - Oncology
Companies developing cancer therapeutics, diagnostics, and precision oncology tools
Immunotherapy & Immuno-Oncology78
Targeted Therapy & Precision Oncology95
Cell & Gene Therapy for Cancer35
Radiopharmaceuticals & ADCs11
Cancer Diagnostics & Biomarkers28
 LLY | Eli Lilly & Co. | Targeted Therapy & Precision Oncology | $1.0t | $1177.40 | +0.6% | 1.1M |
 JNJ | Johnson & Johnson | Immunotherapy & Immuno-Oncology | $0.6t | $261.50 | +2.1% | 4.2M |
 ABBV | ABBVIE INC. | Immunotherapy & Immuno-Oncology | $464.4b | $276.25 | +1.5% | 2.6M |
 MRK | Merck & Co., Inc. | Immunotherapy & Immuno-Oncology | $356.0b | $146.15 | +2.3% | 6.3M |
 AZN | AstraZeneca PLC | Immunotherapy & Immuno-Oncology | $243.3b | $159.12 | +0.3% | 1.7M |
 AMGN | Amgen Inc | Immunotherapy & Immuno-Oncology | $217.9b | $415.22 | +1.8% | 1.4M |
 GILD | Gilead Sciences Inc | Cell & Gene Therapy for Cancer | $179.5b | $151.12 | +2.8% | 3.6M |
 BMY | Bristol-Myers Squibb Co. | Immunotherapy & Immuno-Oncology | $124.9b | $59.27 | -0.7% | 7.4M |
 MRNA | Moderna, Inc. Common Stock | Immunotherapy & Immuno-Oncology | $75.9b | $225.44 | +14.2% | 27.1M |
 REGN | Regeneron Pharmaceuticals Inc | Immunotherapy & Immuno-Oncology | $75.7b | $746.75 | +1.0% | 396.3K |
 NTRA | Natera, Inc. Common Stock | Cancer Diagnostics & Biomarkers | $59.1b | $401.31 | +2.5% | 917.9K |
 RVMD | Revolution Medicines, Inc. Common Stock | Targeted Therapy & Precision Oncology | $44.3b | $189.47 | +0.8% | 2.0M |
 RPRX | Royalty Pharma plc Class A Ordinary Shares | Immunotherapy & Immuno-Oncology | $25.5b | $57.09 | +1.2% | 2.2M |
 GH | Guardant Health, Inc. Common Stock | Cancer Diagnostics & Biomarkers | $23.9b | $167.75 | +1.1% | 1.3M |
 INCY | Incyte Genomics Inc | Targeted Therapy & Precision Oncology | $23.4b | $113.30 | +0.0% | 852.7K |
 JAZZ | Jazz Pharmaceuticals, Inc. | Targeted Therapy & Precision Oncology | $15.3b | $218.50 | -1.9% | 1.1M |
 EXEL | Exelixis Inc | Targeted Therapy & Precision Oncology | $14.5b | $60.06 | +1.4% | 2.2M |
 CORT | Corcept Therapeutics Inc. | Targeted Therapy & Precision Oncology | $12.6b | $121.17 | +2.2% | 411.7K |
 HALO | Halozyme Therapeutics, Inc. | Targeted Therapy & Precision Oncology | $12.5b | $110.43 | +0.5% | 1.6M |
 IBRX | ImmunityBio, Inc. Common Stock | Immunotherapy & Immuno-Oncology | $10.9b | $10.61 | +6.0% | 17.4M |
 NUVL | Nuvalent, Inc. Class A Common Stock | Targeted Therapy & Precision Oncology | $9.8b | $123.96 | 0.0% | N/A |
 CAI | Caris Life Sciences, Inc. Common Stock | Cancer Diagnostics & Biomarkers | $8.0b | $29.57 | +7.9% | 4.3M |
 ACLX | Arcellx, Inc. Common Stock | Cell & Gene Therapy for CancerImmunotherapy & Immuno-Oncology | $6.7b | $115.06 | -0.0% | 16.1M |
 LNTH | Lantheus Holdings, Inc | Radiopharmaceuticals & ADCs | $6.5b | $100.15 | +0.0% | 894.1K |
 IOVA | Iovance Biotherapeutics, Inc. Common Stock | Immunotherapy & Immuno-OncologyCell & Gene Therapy for Cancer | $6.4b | $14.61 | +9.7% | 15.7M |
 GRAL | GRAIL, Inc. Common Stock | Cancer Diagnostics & Biomarkers | $6.4b | $140.50 | +5.9% | 700.2K |
 CGON | CG Oncology, Inc. Common stock | Immunotherapy & Immuno-Oncology | $6.0b | $63.83 | +0.9% | 377.7K |
 COGT | Cogent Biosciences, Inc. Common Stock | Targeted Therapy & Precision Oncology | $5.4b | $31.01 | +3.1% | 1.9M |
 ERAS | Erasca, Inc. Common Stock | Targeted Therapy & Precision Oncology | $5.2b | $15.64 | +3.7% | 6.9M |
 BLLN | BillionToOne, Inc. Class A Common Stock | Cancer Diagnostics & Biomarkers | $5.0b | $97.38 | +2.9% | 294.5K |
 ADPT | Adaptive Biotechnologies Corporation Common Stock | Cancer Diagnostics & Biomarkers | $4.5b | $26.13 | +1.5% | 1.3M |
 ABCL | AbCellera Biologics Inc. Common Shares | Radiopharmaceuticals & ADCs | $4.5b | $12.53 | +4.3% | 4.4M |
 RLAY | Relay Therapeutics, Inc. Common Stock | Targeted Therapy & Precision Oncology | $4.2b | $17.88 | +2.6% | 1.4M |
 TNGX | Tango Therapeutics, Inc. | Targeted Therapy & Precision Oncology | $3.9b | $23.80 | +5.5% | 2.8M |
 VCYT | Veracyte, Inc. | Cancer Diagnostics & Biomarkers | $3.7b | $45.22 | +3.7% | 741.2K |
 IDYA | IDEAYA Biosciences, Inc. Common Stock | Targeted Therapy & Precision Oncology | $3.6b | $36.13 | +0.2% | 577.3K |
 CELC | Celcuity Inc. Common Stock | Targeted Therapy & Precision Oncology | $3.5b | $67.94 | +0.2% | 1.1M |
 ELVN | Enliven Therapeutics, Inc. Common Stock | Targeted Therapy & Precision Oncology | $3.4b | $41.00 | +0.9% | 731.2K |
 RCUS | Arcus Biosciences, Inc. | Immunotherapy & Immuno-Oncology | $3.1b | $24.41 | +2.4% | 622.0K |
 PGEN | Precigen, Inc. Common Stock | Immunotherapy & Immuno-Oncology | $3.1b | $7.80 | +2.8% | 3.0M |
 NRIX | Nurix Therapeutics, Inc. Common stock | Targeted Therapy & Precision Oncology | $2.4b | $22.89 | +0.8% | 1.2M |
 IMNM | Immunome, Inc. | Radiopharmaceuticals & ADCsTargeted Therapy & Precision Oncology | $2.4b | $19.50 | +1.3% | 783.7K |
 NEO | NeoGenomics, Inc. | Cancer Diagnostics & Biomarkers | $2.4b | $16.25 | +2.1% | 1.1M |
 SLS | SELLAS Life Sciences Group, Inc. Common Stock | Immunotherapy & Immuno-Oncology | $2.4b | $11.64 | +3.5% | 3.8M |
 DAWN | Day One Biopharmaceuticals, Inc. Common Stock | Targeted Therapy & Precision Oncology | $2.2b | $21.52 | -0.0% | 3.0M |
 URGN | UroGen Pharma Ltd. Ordinary Shares | Targeted Therapy & Precision Oncology | $2.0b | $36.83 | -0.4% | 751.4K |
 BHVN | Biohaven Ltd. | Targeted Therapy & Precision Oncology | $1.9b | $12.10 | +1.3% | 1.1M |
 VIR | Vir Biotechnology, Inc. Common Stock | Targeted Therapy & Precision Oncology | $1.9b | $11.62 | +5.3% | 1.7M |
 XNCR | Xencor, Inc. | Immunotherapy & Immuno-Oncology | $1.8b | $24.64 | +0.6% | 960.2K |
 NUVB | Nuvation Bio Inc. | Targeted Therapy & Precision Oncology | $1.8b | $5.04 | +1.0% | 2.6M |